Abstract:Background Cisplatin-based adjuvant chemotherapy is the standard of care for patients with resected stage II-IIIA non-small-cell lung cancer (NSCLC). RADIANT and SELECT trial data suggest patients with EGFR-mutant stage IB-IIIA resected NSCLC could benefit from adjuvant EGFR tyrosine kinase inhibitor treatment. We aimed to compare the efficacy of adjuvant gefitinib versus vinorelbine plus cisplatin in patients with completely resected EGFR-mutant stage II-IIIA (N1-N2) NSCLC. Methods We did a randomised, open-label, phase 3 trial at 27 centres in China. We enrolled patients aged 18-75 years with completely resected (R0), stage II-IIIA (N1-N2), EGFR-mutant (exon 19 deletion or exon 21 Leu858Arg) NSCLC. Patients were stratified by N stage and EGFR mutation status and randomised (1: 1) by Pocock and Simon minimisation with a random element to either gefitinib (250 mg once daily) for 24 months or intravenous vinorelbine (25 mg/m(2) on days 1 and 8) plus intravenous cisplatin (75 mg/m(2) on day 1) every 3 weeks for four cycles. The primary endpoint was disease-free survival in the intention-to-treat population, which comprised all randomised patients; the safety population included all randomised patients who received at least one dose of study medication. Enrolment to the study is closed but survival follow-up is ongoing. The study is registered with ClinicalTrials.gov, number NCT01405079. Findings Between Sept 19, 2011, and April 24, 2014, 483 patients were screened and 222 patients were randomised, 111 to gefitinib and 111 to vinorelbine plus cisplatin. Median follow-up was 36 . 5 months (IQR 23 . 8-44 . 8). Median disease-free survival was significantly longer with gefitinib (28 . 7 months [95% CI 24 . 9-32 . 5]) than with vinorelbine plus cisplatin (18 . 0 months [13 . 6-22 . 3]; hazard ratio [HR] 0 . 60, 95% CI 0 . 42-0 . 87; p=0 . 0054). In the safety population, the most commonly reported grade 3 or worse adverse events in the gefitinib group (n=106) were raised alanine aminotransferase and asparate aminotransferase (two [2%] patients with each event vs none with vinorelbine plus cisplatin). In the vinorelbine plus cisplatin group (n=87), the most frequently reported grade 3 or worse adverse events were neutropenia (30 [34%] patients vs none with gefitinib), leucopenia (14 [16%] vs none), and vomiting (eight [9%] vs none). Serious adverse events were reported for seven (7%) patients who received gefitinib and 20 (23%) patients who received vinorelbine plus cisplatin. No interstitial lung disease was noted with gefitinib. No deaths were treatment related. Interpretation Adjuvant gefitinib led to significantly longer disease-free survival compared with that for vinorelbine plus cisplatin in patients with completely resected stage II-IIIA (N1-N2) EGFR-mutant NSCLC. Based on the superior disease-free survival, reduced toxicity, and improved quality of life, adjuvant gefitinib could be a potential treatment option compared with adjuvant chemotherapy in these patients. However, the duration of benefit with gefitinib after 24 months might be limited and overall survival data are not yet mature.

Gefitinib (G) Versus Vinorelbine+cisplatin (VP) As Adjuvant Treatment in Stage II-IIIA (N1-N2) Non-Small-cell Lung Cancer (NSCLC) with EGFR-activating Mutation (ADJUVANT): A Randomized, Phase III Trial (CTONG 1104).

Gefitinib Versus Vinorelbine Plus Cisplatin As Adjuvant Treatment for Stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a Randomised, Open-Label, Phase 3 Study

Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial

Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial.

Gefitinib Plus Chemotherapy Versus Placebo Plus Chemotherapy in Egfr-Mutation- Positive Non-Small-Cell Lung Cancer after Progression on First-Line Gefitinib (impress): A Phase 3 Randomised Trial

First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study.

Icotinib Versus Vinorelbine/platinum As Adjuvant Therapy in Stage II-IIIA Non-Small Cell Lung Cancer with EGFR-mutations: A Multicenter, Randomized, Positive-Controlled, Phase 3, Indication-Expanding Study (EVIDENCE, CCTC-1501).

CTONG1104: Adjuvant Gefitinib Versus Chemotherapy for Resected N1-N2 NSCLC with EGFR Mutation-Final Overall Survival Analysis of the Randomized Phase III Trial 1 Analysis of the Randomized Phase III Trial.

P2.03-047 The Main Treatment Failure Pattern for Completely Resected Stage II–IIIA (N1–N2) EGFR-Mutation Positive Lung Cancer

JCES 01.10 The Main Treatment Failure Pattern for Completely Resected Stage II–IIIA (N1–N2) EGFR-Mutation Positive Lung Cancer

Pemetrexed-carboplatin Adjuvant Chemotherapy with or Without Gefitinib in Resected Stage IIIA-N2 Non-Small Cell Lung Cancer Harbouring EGFR Mutations: A Randomized Phase II Study.

Quality of life with adjuvant gefitinib versus vinorelbine plus cisplatin in patients with completely resected stage II–IIIA (N1–N2) EGFR-mutant non-small-cell lung cancer: Results from the ADJUVANT (CTONG1104) study

Icotinib Versus Chemotherapy As Adjuvant Treatment for Stage II–IIIA EGFR-mutant Non-Small-cell Lung Cancer (EVIDENCE): a Randomised, Open-Label, Phase 3 Trial

Erlotinib Versus Vinorelbine Plus Cisplatin As Adjuvant Therapy in Chinese Patients with Stage IIIA EGFR Mutation-Positive Non-Small-cell Lung Cancer (EVAN): a Randomised, Open-Label, Phase 2 Trial.

CTONG 1103: Erlotinib Versus Gemcitabine Plus Cisplatin As Neo-Adjuvant Treatment for Stage IIIA-N2 EGFR-mutation Non-Small Cell Lung Cancer (EMERGING): A Randomised Study

Neoadjuvant Gefitinib for Stage II-IIIA NSCLC with Activating EGFR Mutation (NCT01833572): an Open-Label, Single-Arm, Phase II Study.

Gefitinib or Erlotinib Vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival

Fruquintinib with Gefitinib As First-Line Therapy in Patients Carrying EGFR Mutations with Advanced Non-Small Cell Lung Cancer: a Single-Arm, Phase II Study

What We Have Learned From Adjuvant Therapy for Resected EGFR-Mutant Non–Small-Cell Lung Cancer

Phase II trial of gefitinib in pretreated Chinese women with advanced non-small-cell lung cancer